{"gene":"AOC3","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":1996,"finding":"VAP-1 (AOC3) mediates lymphocyte binding to endothelial cells in a sialic acid-dependent manner; desialylation abolishes lymphocyte binding. The mature 170-kDa surface form is a heavily sialylated glycoprotein, and sialic acids are indispensable for VAP-1 adhesive function.","method":"Glycosidase digestion of VAP-1, frozen-section adhesion assay under shear stress, anti-VAP-1 monoclonal antibody blockade","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal glycosidase treatment plus functional adhesion assay, replicated across multiple studies in the corpus","pmids":["8627168"],"is_preprint":false},{"year":1997,"finding":"VAP-1 mediates subtype-specific adhesion of CD8+ T cells and NK cells to peripheral lymph node HEVs under shear in an oligosaccharide-dependent, L-selectin-independent manner. Intravital microscopy confirmed VAP-1 involvement in initial lymphocyte–endothelial contact in vivo.","method":"Frozen-section adhesion assay under shear, anti-VAP-1/anti-L-selectin/anti-α4 integrin mAb blockade, intravital microscopy in rabbit mesenteric venules","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal blocking experiments plus in vivo intravital microscopy, replicated in subsequent studies","pmids":["9254657"],"is_preprint":false},{"year":1998,"finding":"A soluble form of VAP-1 (sVAP-1) circulates in human blood; it is slightly larger (by ~10 kDa) than membrane-bound VAP-1 under non-reducing conditions but migrates similarly after reduction. Circulating sVAP-1 retains the ability to modulate lymphocyte binding to endothelial cells.","method":"Sandwich ELISA with anti-VAP-1 mAbs, immunoblotting under reducing and non-reducing conditions, in vitro lymphocyte adhesion assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ELISA + immunoblot + functional adhesion assay, single lab","pmids":["9686623"],"is_preprint":false},{"year":2000,"finding":"Recombinant VAP-1 cDNA transfected into a non-adherent endothelial cell line reconstitutes shear-dependent lymphocyte binding with preference for CD8+ T cells. CD44 ligation on lymphocytes upregulates VAP-1-dependent adhesion, suggesting CD44 activates the VAP-1 counter-receptor. The RGD motif and enzymatic activity are not required for adhesion.","method":"VAP-1 cDNA transfection into endothelial cell line, flow chamber and rotatory adhesion assays under shear, antibody blockade of lymphocyte surface molecules, enzymatic activity mutagenesis/inhibition","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reconstitution by transfection, functional mutagenesis showing RGD and enzyme activity dispensable for adhesion, multiple orthogonal blocking experiments, single lab","pmids":["10864915"],"is_preprint":false},{"year":2001,"finding":"VAP-1 functions as a molecular brake during granulocyte rolling in vivo: anti-VAP-1 mAb treatment in rabbits increased rolling velocity, increased rolling skipping frequency, and reduced firm leukocyte adhesion by ~44%, attenuating ~70% of granulocyte extravasation into an inflammation site.","method":"Intravital microscopy in rabbit inflammation model, anti-VAP-1 mAb blockade","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo intravital microscopy with mAb blockade, quantitative rolling/adhesion measurements, single lab","pmids":["11156953"],"is_preprint":false},{"year":2004,"finding":"The amine oxidase (enzymatic) activity of VAP-1 is required for PMN transmigration through endothelium: an enzymatically inactive point mutant of VAP-1 abolished transmigration capacity, and specific amine oxidase inhibitors reduced PMN rolling and transmigration under shear stress in vitro and PMN extravasation in vivo.","method":"Enzymatically inactive VAP-1 point mutant, amine oxidase inhibitors, flow-dependent in vitro transmigration assay, in vivo animal inflammation model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — point mutant plus pharmacological inhibition plus in vivo model, multiple orthogonal approaches, replicated in subsequent studies","pmids":["14726375"],"is_preprint":false},{"year":2004,"finding":"Adipocytes (3T3-L1 cells and human adipose tissue explants) are a source of soluble VAP-1/SSAO generated by metalloprotease-dependent shedding of the membrane form. TNF-α stimulates and insulin modulates this release; metalloprotease inhibitor batimastat blocks it.","method":"Detection of sVAP-1 in adipocyte conditioned medium by immunoprecipitation and SSAO activity assay, batimastat (metalloprotease inhibitor) blockade, partial adipose tissue ablation in rats","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple cell systems (murine 3T3-L1, human explants, in vivo ablation), pharmacological blockade identifying metalloprotease mechanism, single lab","pmids":["14968297"],"is_preprint":false},{"year":2005,"finding":"AOC3/VAP-1-deficient mice show defective leukocyte slow rolling, firm adhesion, and transmigration at inflammatory sites and lymphoid tissues, with reduced lymphocyte homing to lymphoid organs and attenuated peritonitis response, establishing AOC3 as essential for leukocyte extravasation in vivo.","method":"AOC3 knockout mice, real-time intravital imaging, peritonitis model, lymphocyte homing assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple in vivo readouts and real-time imaging, replicated across multiple inflammation models","pmids":["15664163"],"is_preprint":false},{"year":2006,"finding":"Fetal VAP-1 is expressed from embryonic week 7 in smooth muscle, is dimerized and enzymatically active before birth, and can mediate rolling and firm adhesion of cord blood lymphocytes on HUVEC under shear stress, indicating the protein is functionally intact during human ontogeny.","method":"Immunohistochemistry of fetal tissues, adenoviral VAP-1 transfection of HUVEC, flow chamber adhesion assay with cord blood lymphocytes, enzymatic activity measurement","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — adenoviral transfection plus flow chamber functional assay, single lab","pmids":["16556889"],"is_preprint":false},{"year":2007,"finding":"The oxidase activity of VAP-1 induces transcription and translation of endothelial E- and P-selectins, thereby promoting leukocyte binding. In VAP-1-deficient mice reconstituted with human VAP-1 transgene, enzyme-dependent P-selectin upregulation was confirmed in HEVs and flat-walled vessels in vivo.","method":"Wild-type and enzymatically inactive VAP-1 point mutant transfected endothelial cells, VAP-1 KO mice, humanized VAP-1 transgenic mice, selectin transcription/translation assays, lymphocyte binding assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — enzymatic point mutant plus KO rescue transgenic mice, in vitro and in vivo validation, multiple orthogonal readouts, single lab","pmids":["17548577"],"is_preprint":false},{"year":2007,"finding":"AOC3/VAP-1-deficient mice have reduced IgA concentrations, age-dependent paucity of Peyer's patch lymphocytes, and impaired oral OVA immunization and antimicrobial responses (S. aureus, coxsackie B4), establishing a role for VAP-1 in mucosal immunity.","method":"VAP-1 KO mice, oral immunization with OVA, bacterial/viral challenge, flow cytometry, immunoglobulin measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with multiple immune readouts, single lab","pmids":["17947691"],"is_preprint":false},{"year":2007,"finding":"SSAO/VAP-1 oxidizes primary amines in adipocytes; substrates including benzylamine and methylamine stimulate glucose transport via an oxidation-dependent (not receptor-mediated) mechanism. AOC3 knockout adipocytes completely lacked the SSAO-dependent glucose uptake response to benzylamine, methylamine, and tyramine.","method":"AOC3 knockout mice, hexose transport assay in isolated adipocytes, SSAO activity measurement","journal":"Journal of neural transmission","confidence":"High","confidence_rationale":"Tier 2 / Strong — definitive genetic KO abolishing both enzymatic and functional response, replicated in subsequent benzylamine studies","pmids":["17406965"],"is_preprint":false},{"year":2008,"finding":"SSAO/VAP-1 transmembrane form mediates vascular cell death via methylamine oxidation; the catalytic products activate p53 phosphorylation, induce PUMA-α expression, affect mitochondrial Bcl-2 family proteins, and activate effector caspases, causing cytotoxicity in smooth muscle cells.","method":"Stably transfected SSAO-expressing smooth muscle cell line (A7r5), methylamine treatment, cytotoxicity assay, western blot for p53, PUMA-α, Bcl-2 family, caspase activity assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stably transfected cell line with substrate treatment, multiple molecular pathway readouts, single lab","pmids":["18348872"],"is_preprint":false},{"year":2008,"finding":"VAP-1 deficiency in mice attenuates intestinal ischemia-reperfusion injury and acute lung injury. Both enzymatic inhibitors and a function-blocking mAb in wild-type mice replicate the protective phenotype, establishing the catalytic activity of VAP-1 as responsible for its pro-inflammatory action in I/R injury.","method":"VAP-1 KO mice, humanized transgenic VAP-1 mice, small molecule enzyme inhibitors, function-blocking mAb, intestinal I/R model with lung injury readout","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO + pharmacological inhibitors + mAb blockade + transgenic rescue, multiple orthogonal approaches","pmids":["18991279"],"is_preprint":false},{"year":2011,"finding":"Crystal structures of soluble AOC3 from human plasma revealed two imidazole-binding sites: one at the TPQ cofactor (in both off-copper and on-copper conformations) and one in the substrate channel near Tyr394 and Thr212. Single-mutant functional studies identified Met211 and Leu469 as key residues for substrate specificity.","method":"X-ray crystallography of soluble human AOC3 (2.6 Å and 2.95 Å resolution), site-directed mutagenesis of Met211, Tyr394, Thr212, Leu469, enzyme activity assays with four substrates, computational docking","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures plus mutagenesis plus enzyme activity assays, single lab but multiple orthogonal methods","pmids":["21585208"],"is_preprint":false},{"year":2011,"finding":"Human AOC3 expressed in insect cells oxidizes a broad range of primary amines including dopamine and cysteamine; kinetic profiling shows K(m)(O2) approximates interstitial oxygen partial pressure. Differentiated murine 3T3-L1 adipocytes display uniform cell-surface AOC3 with whole-cell K(m) values close to those of purified enzyme, linking kinetic parameters to adipocyte function.","method":"Purified recombinant human and murine AOC3 from insect cells, substrate kinetic profiling, K(m)(O2) measurement, whole-cell kinetics with differentiated 3T3-L1 adipocytes","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic characterization of purified recombinant protein plus cell-based validation, single lab, multiple substrates and conditions","pmids":["22238597"],"is_preprint":false},{"year":2011,"finding":"VAP-1 kinetics studied using isotope effects (KIE of 6–7.6 on k(cat)/K(m) with d2-benzylamine; large KIE on k(cat) ~8 with phenylethylamine) established that C-H bond breaking at the TPQ cofactor is the rate-limiting step for substrate oxidation.","method":"Soluble VAP-1 expressed in HEK293 EBNA1 cells, steady-state kinetics, primary kinetic isotope effects with deuterated substrates, pH-rate profiles, QSAR analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous mechanistic enzymology with isotope effects and pH profiles, single lab","pmids":["21737458"],"is_preprint":false},{"year":2011,"finding":"VAP-1 expressed in endothelial cells localizes specifically to lipid rafts of the plasma membrane as a dimer, retains enzymatic activity comparable to in vivo, and mediates leukocyte adhesion to endothelium; this adhesion function is not observed in smooth muscle cell lines expressing 3-fold higher VAP-1, indicating cell-type-specific functional context.","method":"Stable transfection of human SSAO/VAP-1 into endothelial cell line, lipid raft fractionation, western blot, leukocyte adhesion assay, SSAO enzyme activity assay","journal":"Biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable transfection + lipid raft fractionation + functional adhesion assay, single lab","pmids":["21819380"],"is_preprint":false},{"year":2011,"finding":"VAP-1 inhibition blocks IL-1β-induced but not VEGF-A-induced lymphangiogenesis and angiogenesis in the mouse cornea, and this effect is mediated by blockade of M2 macrophage infiltration. VAP-1 was expressed in blood vessels but not in lymphatic vessels in vivo.","method":"Corneal micropocket assay with IL-1β or VEGF-A, VAP-1 inhibitor treatment, in vivo molecular imaging of VAP-1 expression, macrophage phenotyping","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo model with molecular imaging and pharmacological inhibition, single lab","pmids":["21435467"],"is_preprint":false},{"year":2013,"finding":"Mice carrying an oxidase-activity-null VAP-1 knock-in show the same inflammatory phenotype as VAP-1 null mice in sterile peritonitis and antibody-induced arthritis models, definitively establishing that the oxidase activity is responsible for VAP-1's pro-inflammatory function in vivo.","method":"VAP-1 oxidase-null knock-in mice, sterile peritonitis model, antibody-induced arthritis model, comparison to VAP-1 null mice","journal":"American journal of clinical and experimental immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in point mutant compared to full knockout in two independent disease models, replicates enzymatic activity requirement established in earlier inhibitor studies","pmids":["23885334"],"is_preprint":false},{"year":2013,"finding":"VAP-1 mediates myeloid cell recruitment during pulmonary metastasis; blocking VAP-1 with a small molecule inhibitor reduces myeloid cell accumulation, tumor cell survival, and metastasis. Simultaneous blockade of VCAM-1 and VAP-1 does not produce additive effects, suggesting closely related mechanisms.","method":"VAP-1 small molecule inhibitor, VCAM-1 blocking antibody, murine pulmonary metastasis model, myeloid cell quantification, tumor survival assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological blockade with functional metastasis readout, single lab","pmids":["23407548"],"is_preprint":false},{"year":2013,"finding":"VAP-1 and α4 integrin mediate opposing immune cell recruitment in concanavalin A hepatitis: anti-VAP-1 antibody (blocking adhesion but not amine oxidase activity) reduces IL-4-producing CD4 T cell infiltration and liver injury, while VAP-1-deficient mice show complete abrogation of both activities, confirming VAP-1-dependent CD4 T cell homing to the liver.","method":"Anti-VAP-1 mAb, anti-α4 integrin mAb, VAP-1 KO mice, Con A hepatitis model, intravital microscopy, T cell phenotyping","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — mAb blockade plus genetic KO, multiple cell population readouts, distinguishes adhesion from enzymatic activity contributions","pmids":["23686782"],"is_preprint":false},{"year":2013,"finding":"Crystal structures of novel pyridazinone inhibitors in complex with human VAP-1 defined a unique reversible binding site in the active site channel distinct from covalent substrate-based binding; homology modeling identified species-specific amino acid differences explaining the lack of rodent VAP-1 inhibition.","method":"X-ray crystallography of inhibitor–hVAP-1 complexes (3 structures), homology modeling, inhibitory activity assays against human and rodent VAP-1","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple crystal structures plus enzyme activity assays, single lab","pmids":["24304424"],"is_preprint":false},{"year":2014,"finding":"SSAO/VAP-1 in endothelial cells exacerbates oxygen-glucose deprivation (OGD) damage; methylamine oxidation during OGD increases cell death via caspase-3 and caspase-8 activation. OGD also triggers metalloproteinase-2-dependent shedding of soluble SSAO/VAP-1 and induces SSAO-dependent leukocyte adhesion partly through its enzymatic activity.","method":"Stably transfected hSSAO/VAP-1 endothelial cell line, OGD model, metalloproteinase inhibitors, western blot for caspases, leukocyte adhesion assay, SSAO enzymatic substrate treatment","journal":"Cerebrovascular diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable transfection plus pharmacological inhibition plus multiple functional readouts, single lab","pmids":["24503888"],"is_preprint":false},{"year":2014,"finding":"SSAO/VAP-1 enhances Aβ1-40 (Dutch mutant) and Aβ1-42 deposition on vascular cells by mechanisms both dependent and independent of its enzymatic activity. Conversely, Dutch-mutated Aβ1-40 increases SSAO-dependent cell toxicity and increases SSAO protein availability at endothelial membranes, establishing a bidirectional cross-talk between SSAO and Aβ in CAA pathology.","method":"Vascular cell models stably expressing SSAO, Aβ peptide treatment, SSAO enzymatic activity inhibition, Aβ deposition quantification, cell toxicity assay","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable expression system with enzymatic inhibition distinguishing activity-dependent and -independent mechanisms, single lab","pmids":["25457560"],"is_preprint":false},{"year":2019,"finding":"SSAO/VAP-1 expression in endothelial cells alters the pro-inflammatory and pro-angiogenic angioneurin release (particularly IL-6, IL-8, VEGF), decreases tight-junction proteins (zona occludens, claudin-5), increases BBB permeability and leukocyte adhesion, and enhances vascular Aβ deposition by mechanisms both dependent and independent of enzymatic activity, linking SSAO to BBB dysfunction in Alzheimer's disease.","method":"In vitro BBB models (hCMEC/D3 cells expressing or not expressing hSSAO/VAP-1), cytokine ELISA, western blot for tight-junction proteins, permeability assay, leukocyte adhesion assay, Aβ deposition assay","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isogenic cell lines differing only in SSAO expression, multiple orthogonal readouts, single lab","pmids":["31047972"],"is_preprint":false},{"year":2020,"finding":"The obesity phenotype of AOC3 knockout mice (increased adiposity, loss of benzylamine insulin-like action in adipocytes, downregulated adipose inflammatory markers) is fully reproduced in AOC3 knock-in mice expressing oxidase-activity-null VAP-1, establishing that the SSAO enzymatic activity is required for the metabolic functions of VAP-1 in adipose tissue.","method":"AOC3 KO mice vs. AOC3 oxidase-activity knock-in mice, body composition, adipocyte glucose transport assay, lipid profile, adipose tissue inflammation markers, SSAO activity measurement","journal":"Journal of physiology and biochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — parallel KO and enzymatic knock-in comparison across multiple metabolic readouts, two independent genetic models","pmids":["32712883"],"is_preprint":false},{"year":2021,"finding":"AOC3/VAP-1 is a transcriptional target of myocardin-related transcription factors (MRTFs: MYOCD, MRTF-A/MKL1, MRTF-B/MKL2) acting through serum response factor (SRF) in smooth muscle cells. MRTF overexpression increases AOC3 mRNA and protein; SRF silencing reduces AOC3 transcript levels; AOC3 promoter reporter activity is increased by MRTF-A and depends on chromatin remodeling enzyme KDM3A.","method":"Bioinformatics correlation, MRTF overexpression in human SMCs, SRF siRNA knockdown, promoter-reporter assay, qPCR, western blot, immunofluorescence imaging","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter plus overexpression plus knockdown with multiple readouts, single lab","pmids":["33727640"],"is_preprint":false},{"year":2010,"finding":"In mouse adipose tissue, histamine is oxidized predominantly by SSAO (AOC3 product): AOC3 knockout abolished histamine oxidation in adipose tissue but not in intestine, where diamine oxidase (AOC1) predominates. Loss of adipose SSAO-mediated histamine oxidation unmasked a lipolytic effect of histamine in adipocytes.","method":"AOC3 KO mice, tissue amine oxidase activity assay (hydrogen peroxide production), lipolysis assay (glycerol release) in isolated adipocytes, real-time PCR for AOC1/AOC2/MAOA/MAOB","journal":"Inflammation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with multiple tissue and functional readouts, discriminates AOC3 from related enzymes","pmids":["20012150"],"is_preprint":false},{"year":2016,"finding":"AOC3 is a marker of myofibroblasts (identified as the target of mAb PR2D3) and is expressed on the cell surface in a trypsin- and collagenase-sensitive manner. TGFβ substantially downregulates AOC3 expression in myofibroblasts but dramatically increases αSMA in skin fibroblasts, distinguishing these two cell types.","method":"Identification of AOC3 as mAb PR2D3 target protein, surface trypsin/collagenase digestion assay, FACS sorting, TGFβ treatment, whole-genome microarray, NKX2-3 knockdown, qPCR/western blot","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mAb target identification plus multiple functional cell biology assays, single lab","pmids":["27036009"],"is_preprint":false},{"year":2022,"finding":"AOC3 knockout in ApoE-/- mice paradoxically increased atherosclerotic plaque size at early stages, associated with VSMC dedifferentiation, decreased contractile markers, increased MCP-1, and higher CD3+ T cell recruitment. AOC3 was confirmed to be expressed mainly by VSMCs and slightly by endothelium, but not by macrophages in plaques.","method":"ApoE-/-/AOC3-/- double knockout mice, immunohistochemistry, western blot, confocal microscopy, qPCR, human VSMC treatment with AOC3 inhibitor LJP1586","journal":"Frontiers in cardiovascular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO in atherosclerosis model with multiple cell markers and in vitro validation, single lab","pmids":["36176983"],"is_preprint":false},{"year":2024,"finding":"AOC3 promotes lung metastasis of osteosarcoma by recruiting tumor-associated neutrophils; activated neutrophil extracellular traps (NETs) upregulate metastatic capacity of OS cells, and AOC3 also supports tumor neovascularization. Downregulation of AOC3 inhibits OS cell migration, invasion, and angiogenesis in vitro and reduces lung metastasis in vivo, mediated through NF-κB/IL-8 signaling.","method":"siRNA knockdown of AOC3 in OS cells, transwell/wound healing assay, tube formation assay, sphere-forming assay, C57BL/6 xenograft lung metastasis model, flow cytometry for neutrophil recruitment, immunofluorescence for NETs, ELISA","journal":"Heliyon","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro knockdown plus in vivo xenograft model, multiple functional readouts, single lab","pmids":["39296147"],"is_preprint":false},{"year":2017,"finding":"Simvastatin blocks soluble SSAO/VAP-1 release into the bloodstream after ischemic stimulus and prevents E-selectin and VCAM-1 overexpression, in part through interaction with SSAO/VAP-1-dependent pathways, while not acting as a direct enzymatic inhibitor of SSAO in vitro.","method":"In vitro ischemia model in hSSAO/VAP-1-expressing endothelial cells, in vivo stroke model, SSAO activity assay, western blot for E-selectin and VCAM-1, leukocyte adhesion assay","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isogenic cell lines expressing or not expressing SSAO, in vivo stroke model, but simvastatin mechanism indirect, single lab","pmids":["29175057"],"is_preprint":false}],"current_model":"AOC3/VAP-1 is a homodimeric, cell-surface copper-containing amine oxidase expressed on endothelial cells, smooth muscle cells, and adipocytes that possesses both adhesive and enzymatic functions: its TPQ cofactor oxidizes primary amines to produce hydrogen peroxide, ammonia, and aldehydes, and this catalytic activity is required (as shown by enzymatically inactive point mutants and knockout mice) for leukocyte slow rolling, firm adhesion, and transmigration at inflammatory sites, in part by inducing endothelial P- and E-selectin expression; the soluble form is shed by metalloprotease-dependent cleavage; in adipocytes the enzyme mediates SSAO-substrate-stimulated glucose uptake; and the protein's transcription in smooth muscle cells is driven by the MRTF-SRF pathway via KDM3A-dependent chromatin remodeling."},"narrative":{"mechanistic_narrative":"AOC3/VAP-1 is a homodimeric, sialylated cell-surface copper-containing amine oxidase that couples a dual adhesive and enzymatic role in directing leukocyte traffic across endothelium during inflammation [PMID:8627168, PMID:15664163]. It mediates shear-resistant, oligosaccharide-dependent binding of CD8+ T cells and NK cells to high endothelial venules independently of L-selectin, and acts as a molecular brake on leukocyte rolling that promotes firm adhesion and transmigration in vivo [PMID:9254657, PMID:10864915, PMID:11156953]. Genetic ablation establishes AOC3 as essential for leukocyte slow rolling, firm adhesion, extravasation, lymphocyte homing, and mucosal immunity [PMID:15664163, PMID:17947691]. The enzymatic and adhesive functions are mechanistically linked: the TPQ-cofactor-dependent oxidation of primary amines is required for transmigration and drives transcriptional induction of endothelial E- and P-selectins, and oxidase-activity-null knock-in mice phenocopy the full knockout in sterile peritonitis and arthritis, definitively assigning the pro-inflammatory action to catalysis [PMID:14726375, PMID:17548577, PMID:23885334]. Mechanistic enzymology and crystallography of the soluble form define a TPQ cofactor with rate-limiting C–H bond cleavage, copper-coordinating active-site geometry, and substrate-specificity residues (Met211, Leu469) within the substrate channel [PMID:21585208, PMID:21737458]. In adipose tissue the same oxidase activity mediates amine-substrate-stimulated glucose uptake and an insulin-like metabolic action, with knock-in studies showing enzymatic activity is required for the metabolic phenotype [PMID:17406965, PMID:32712883]. A soluble form is generated by metalloprotease-dependent shedding from adipocytes and endothelium and circulates in blood [PMID:9686623, PMID:14968297]. AOC3 transcription in smooth muscle cells is driven by myocardin-related transcription factors acting through SRF and KDM3A-dependent chromatin remodeling [PMID:33727640].","teleology":[{"year":1996,"claim":"Established that VAP-1's adhesive activity toward lymphocytes depends on its heavy sialylation, defining it as a glycosylation-dependent endothelial adhesion molecule before its enzymatic identity was known.","evidence":"Glycosidase digestion plus frozen-section adhesion under shear and mAb blockade","pmids":["8627168"],"confidence":"High","gaps":["Molecular identity of the lymphocyte counter-receptor not defined","Relationship between adhesion and any catalytic function not yet addressed"]},{"year":1997,"claim":"Demonstrated subtype-specific, L-selectin-independent adhesion of CD8+ T and NK cells to HEVs and confirmed VAP-1 involvement in initial lymphocyte–endothelial contact in vivo.","evidence":"Frozen-section shear adhesion with orthogonal mAb blockade and rabbit intravital microscopy","pmids":["9254657"],"confidence":"High","gaps":["Counter-receptor still unidentified","Mechanistic basis of cell-type preference unknown"]},{"year":1998,"claim":"Identified a circulating soluble form of VAP-1 retaining adhesion-modulating activity, raising the possibility of a regulated shed pool.","evidence":"Sandwich ELISA, reducing/non-reducing immunoblot, and in vitro adhesion assay","pmids":["9686623"],"confidence":"Medium","gaps":["Mechanism and protease responsible for shedding not defined","Physiological role of soluble form unresolved"]},{"year":2000,"claim":"Reconstitution by transfection proved VAP-1 is sufficient to confer shear-dependent CD8+ adhesion and showed RGD motif and enzymatic activity are dispensable for adhesion itself, separating adhesion from catalysis.","evidence":"VAP-1 cDNA transfection, flow chamber adhesion, lymphocyte mAb blockade, activity mutagenesis","pmids":["10864915"],"confidence":"High","gaps":["CD44-VAP-1 counter-receptor link inferred but not molecularly mapped","Did not reconcile enzyme-independent adhesion with later enzyme-dependent transmigration"]},{"year":2001,"claim":"Defined VAP-1 functionally as a molecular brake on granulocyte rolling that converts rolling to firm adhesion and enables extravasation in vivo.","evidence":"Rabbit intravital microscopy with quantitative rolling/adhesion measurements and mAb blockade","pmids":["11156953"],"confidence":"High","gaps":["Did not establish whether enzymatic activity underlies the braking effect"]},{"year":2004,"claim":"Showed that the amine oxidase activity is required for PMN transmigration, linking catalysis to leukocyte trafficking for the first time.","evidence":"Enzymatically inactive point mutant, amine oxidase inhibitors, flow transmigration assay, in vivo model","pmids":["14726375"],"confidence":"High","gaps":["Downstream effectors of the oxidase products not identified at this stage"]},{"year":2004,"claim":"Identified adipocytes as a source of soluble VAP-1 generated by metalloprotease-dependent shedding regulated by TNF-α and insulin, defining how the soluble pool arises.","evidence":"Adipocyte conditioned-medium immunoprecipitation/SSAO assay with batimastat blockade and in vivo adipose ablation","pmids":["14968297"],"confidence":"High","gaps":["Specific metalloprotease not identified","Functional consequence of shed enzyme not resolved here"]},{"year":2005,"claim":"Genetic knockout established AOC3 as essential for leukocyte slow rolling, firm adhesion, transmigration, and lymphocyte homing in vivo.","evidence":"AOC3 knockout mice with real-time intravital imaging, peritonitis, and homing assays","pmids":["15664163"],"confidence":"High","gaps":["Did not isolate enzymatic from adhesive contribution genetically"]},{"year":2007,"claim":"Connected oxidase activity to a transcriptional output by showing enzyme-dependent induction of endothelial E- and P-selectins, providing a molecular bridge between catalysis and adhesion.","evidence":"WT vs enzyme-null point-mutant endothelial cells, KO and humanized transgenic mice, selectin transcription/translation assays","pmids":["17548577"],"confidence":"High","gaps":["Signaling pathway from H2O2/aldehyde products to selectin transcription not fully mapped"]},{"year":2007,"claim":"Extended AOC3 function to mucosal immunity, showing KO mice have reduced IgA, Peyer's patch defects, and impaired oral/antimicrobial responses.","evidence":"AOC3 KO mice with oral immunization, pathogen challenge, and immunoglobulin measurement","pmids":["17947691"],"confidence":"High","gaps":["Cellular mechanism linking VAP-1 to IgA and Peyer's patch development unclear"]},{"year":2007,"claim":"Demonstrated that adipocyte AOC3 oxidase activity mediates amine-substrate-stimulated glucose transport via an oxidation-dependent, non-receptor mechanism.","evidence":"AOC3 KO adipocyte hexose transport assays with multiple amine substrates and SSAO activity measurement","pmids":["17406965"],"confidence":"High","gaps":["Molecular link between oxidation products and glucose transporter mobilization not defined"]},{"year":2008,"claim":"Showed catalytic products of methylamine oxidation can drive vascular smooth muscle cytotoxicity via p53/PUMA/caspase signaling, implicating the enzyme in cell death.","evidence":"Stably transfected SSAO smooth muscle cells with methylamine treatment and apoptotic pathway western blots/caspase assays","pmids":["18348872"],"confidence":"Medium","gaps":["Overexpression system; physiological substrate concentrations not validated","In vivo relevance not established"]},{"year":2010,"claim":"Identified histamine as a tissue-selective AOC3 substrate in adipose tissue and revealed that its oxidation restrains a lipolytic effect, distinguishing AOC3 from AOC1.","evidence":"AOC3 KO mice, tissue amine oxidase and lipolysis assays, expression profiling of related enzymes","pmids":["20012150"],"confidence":"High","gaps":["Physiological regulation of histamine oxidation in human adipose not addressed"]},{"year":2011,"claim":"Solved crystal structures of soluble human AOC3 and defined active-site/substrate-channel residues governing substrate specificity, providing a structural framework for catalysis and inhibitor design.","evidence":"X-ray crystallography at 2.6/2.95 Å with site-directed mutagenesis and substrate activity assays","pmids":["21585208"],"confidence":"High","gaps":["Structure of the membrane-bound full-length dimer not determined"]},{"year":2011,"claim":"Established C–H bond cleavage at the TPQ cofactor as the rate-limiting catalytic step through kinetic isotope effects.","evidence":"Steady-state kinetics with deuterated substrates, pH-rate profiles, QSAR on soluble VAP-1","pmids":["21737458"],"confidence":"High","gaps":["Does not address regulation of catalysis in the cellular membrane context"]},{"year":2011,"claim":"Profiled the broad primary-amine substrate range and showed KmO2 approximates interstitial oxygen, linking enzyme kinetics to adipocyte physiology.","evidence":"Purified recombinant human/murine AOC3 kinetics and whole-cell 3T3-L1 adipocyte measurements","pmids":["22238597"],"confidence":"High","gaps":["Identity of the dominant physiological substrate in vivo not resolved"]},{"year":2011,"claim":"Localized active VAP-1 dimers to endothelial lipid rafts and showed adhesion function is cell-type-context dependent, absent in smooth muscle cells despite higher expression.","evidence":"Stable transfection, lipid raft fractionation, adhesion and enzyme assays","pmids":["21819380"],"confidence":"Medium","gaps":["Molecular basis of cell-type-specific adhesion competence unexplained","Single overexpression system"]},{"year":2013,"claim":"Oxidase-activity-null knock-in mice phenocopied full knockout in peritonitis and arthritis, definitively assigning the pro-inflammatory function to catalytic activity.","evidence":"Oxidase-null knock-in mice compared to null mice in two inflammation models","pmids":["23885334"],"confidence":"High","gaps":["Did not address whether residual adhesion contributes in other disease contexts"]},{"year":2013,"claim":"Implicated VAP-1 in pulmonary metastasis through myeloid cell recruitment, with mechanistic overlap with VCAM-1.","evidence":"Small-molecule VAP-1 inhibitor and VCAM-1 mAb in a murine metastasis model with myeloid quantification","pmids":["23407548"],"confidence":"Medium","gaps":["Whether enzymatic vs adhesive activity drives this not separated","Single lab pharmacological approach"]},{"year":2013,"claim":"Distinguished VAP-1's adhesion versus enzymatic contributions in liver inflammation, showing adhesion-blocking mAb reduces CD4 T cell homing while KO abrogates both.","evidence":"Anti-VAP-1 and anti-α4 mAbs, KO mice, Con A hepatitis, intravital microscopy, T cell phenotyping","pmids":["23686782"],"confidence":"High","gaps":["Relative quantitative contribution of adhesion vs catalysis not fully partitioned"]},{"year":2013,"claim":"Defined a reversible pyridazinone inhibitor binding site in the active-site channel and rationalized species-specific inhibition, advancing structure-based drug design.","evidence":"Three inhibitor–hVAP-1 crystal structures, homology modeling, human/rodent activity assays","pmids":["24304424"],"confidence":"High","gaps":["In vivo efficacy of these inhibitors not addressed in this study"]},{"year":2014,"claim":"Linked SSAO/VAP-1 methylamine oxidation to ischemic endothelial death and showed OGD triggers MMP-2-dependent shedding, connecting the enzyme to cerebrovascular injury.","evidence":"Stably transfected endothelial cells under OGD with MMP inhibitors, caspase blots, adhesion assays","pmids":["24503888"],"confidence":"Medium","gaps":["Overexpression system; endogenous relevance untested","MMP-2 as shedding protease shown only pharmacologically"]},{"year":2014,"claim":"Established bidirectional cross-talk between SSAO/VAP-1 and amyloid-β in cerebral amyloid angiopathy, with both enzyme-dependent and -independent components.","evidence":"Vascular cells stably expressing SSAO, Aβ treatment, enzymatic inhibition, deposition and toxicity assays","pmids":["25457560"],"confidence":"Medium","gaps":["Enzyme-independent mechanism of Aβ enhancement not defined","Overexpression model only"]},{"year":2016,"claim":"Identified AOC3 as a surface marker of myofibroblasts that is downregulated by TGFβ, distinguishing it from αSMA-defined fibroblast states.","evidence":"mAb PR2D3 target identification, surface protease digestion, FACS, TGFβ treatment, microarray","pmids":["27036009"],"confidence":"Medium","gaps":["Functional role of AOC3 in myofibroblast biology not established","Mechanism of TGFβ regulation unmapped"]},{"year":2017,"claim":"Showed simvastatin suppresses ischemia-induced soluble SSAO release and selectin/VCAM-1 expression via SSAO-dependent pathways without direct enzyme inhibition.","evidence":"Isogenic SSAO-expressing endothelial cells, in vivo stroke model, activity and adhesion assays","pmids":["29175057"],"confidence":"Medium","gaps":["Indirect mechanism; statin target intersecting SSAO pathway not defined"]},{"year":2019,"claim":"Linked endothelial SSAO/VAP-1 to blood-brain-barrier dysfunction through altered cytokine release, tight-junction loss, increased permeability, and Aβ deposition in Alzheimer's models.","evidence":"Isogenic hCMEC/D3 BBB models with cytokine ELISA, tight-junction blots, permeability and adhesion assays","pmids":["31047972"],"confidence":"Medium","gaps":["In vivo BBB validation lacking","Enzyme-independent component mechanistically unresolved"]},{"year":2020,"claim":"Demonstrated through parallel KO and oxidase-null knock-in mice that SSAO enzymatic activity is required for VAP-1's adipose metabolic functions, mirroring the inflammatory enzyme-dependence.","evidence":"AOC3 KO vs oxidase-null knock-in mice, body composition, adipocyte glucose transport, inflammation markers","pmids":["32712883"],"confidence":"High","gaps":["Downstream effector linking oxidation to insulin-like glucose uptake not identified"]},{"year":2021,"claim":"Defined the transcriptional control of AOC3 in smooth muscle cells, identifying it as an MRTF/SRF target dependent on KDM3A-mediated chromatin remodeling.","evidence":"MRTF overexpression, SRF siRNA, promoter-reporter assays, qPCR/western blot in human SMCs","pmids":["33727640"],"confidence":"Medium","gaps":["Upstream signals activating MRTF/SRF on the AOC3 locus not defined","In vivo confirmation lacking"]},{"year":2022,"claim":"Revealed a paradoxical protective role for AOC3 in early atherosclerosis, where KO increased plaque size and VSMC dedifferentiation, confirming VSMC-dominant expression in plaques.","evidence":"ApoE-/-/AOC3-/- mice, immunohistochemistry, contractile marker blots, human VSMC inhibitor treatment","pmids":["36176983"],"confidence":"Medium","gaps":["Mechanism by which AOC3 loss promotes VSMC dedifferentiation unresolved","Stage-dependence not fully characterized"]},{"year":2024,"claim":"Showed AOC3 promotes osteosarcoma lung metastasis by recruiting tumor-associated neutrophils and driving NET formation and angiogenesis via NF-κB/IL-8 signaling.","evidence":"AOC3 siRNA knockdown, migration/invasion/tube/sphere assays, xenograft metastasis model, NET imaging","pmids":["39296147"],"confidence":"Medium","gaps":["Enzymatic vs adhesive contribution not separated","Direct AOC3-NF-κB/IL-8 link not mechanistically defined"]},{"year":null,"claim":"The molecular identity of the lymphocyte/leukocyte counter-receptor and the precise signaling chain connecting amine-oxidation products (H2O2, aldehyde, ammonia) to selectin induction and glucose transport remain undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Counter-receptor for VAP-1-mediated adhesion not molecularly identified","Signal transduction from oxidase products to transcriptional and metabolic outputs incompletely mapped","Structure of full-length membrane dimer unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[5,9,11,14,15,16,28]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,1,3,4,7]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[11,15,16]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,5,9,17]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,6]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,5,7,9,10,19,21]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[11,26,28]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,1,3,4]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16853","full_name":"Amine oxidase [copper-containing] 3","aliases":["Amine oxidase copper-containing 3","Copper amine oxidase","HPAO","Semicarbazide-sensitive amine oxidase","SSAO","Vascular adhesion protein 1","VAP-1"],"length_aa":763,"mass_kda":84.6,"function":"Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia (PubMed:19588076, PubMed:24304424, PubMed:9653080). Has a preference for the primary monoamines methylamine and benzylamine (PubMed:19588076, PubMed:9653080). Could also act on 2-phenylethylamine but much less efficiently (PubMed:19588076). At endothelial cells surface can also function as a cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion (PubMed:9254657, PubMed:9653080) Has no semicarbazide-sensitive amine oxidase (SSAO) activity","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q16853/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AOC3","classification":"Not Classified","n_dependent_lines":25,"n_total_lines":1208,"dependency_fraction":0.020695364238410598},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AOC3","total_profiled":1310},"omim":[{"mim_id":"603735","title":"AMINE OXIDASE, COPPER-CONTAINING, 3; AOC3","url":"https://www.omim.org/entry/603735"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adipose tissue","ntpm":397.0},{"tissue":"blood vessel","ntpm":328.7}],"url":"https://www.proteinatlas.org/search/AOC3"},"hgnc":{"alias_symbol":["VAP1","HPAO","VAP-1"],"prev_symbol":[]},"alphafold":{"accession":"Q16853","domains":[{"cath_id":"3.10.450.40","chopping":"66-166","consensus_level":"high","plddt":97.6487,"start":66,"end":166},{"cath_id":"3.10.450.40","chopping":"174-284","consensus_level":"high","plddt":96.4401,"start":174,"end":284},{"cath_id":"2.70.98.20","chopping":"337-392_467-719","consensus_level":"high","plddt":98.3579,"start":337,"end":719}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16853","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16853-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16853-F1-predicted_aligned_error_v6.png","plddt_mean":94.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AOC3","jax_strain_url":"https://www.jax.org/strain/search?query=AOC3"},"sequence":{"accession":"Q16853","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16853.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16853/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16853"}},"corpus_meta":[{"pmid":"16688218","id":"PMC_16688218","title":"Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16688218","citation_count":151,"is_preprint":false},{"pmid":"11274927","id":"PMC_11274927","title":"VAP-1: an adhesin and an enzyme.","date":"2001","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11274927","citation_count":134,"is_preprint":false},{"pmid":"9686623","id":"PMC_9686623","title":"Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9686623","citation_count":131,"is_preprint":false},{"pmid":"15664163","id":"PMC_15664163","title":"Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo.","date":"2005","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15664163","citation_count":107,"is_preprint":false},{"pmid":"14726375","id":"PMC_14726375","title":"Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1).","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14726375","citation_count":107,"is_preprint":false},{"pmid":"14968297","id":"PMC_14968297","title":"Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner.","date":"2004","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/14968297","citation_count":99,"is_preprint":false},{"pmid":"17962625","id":"PMC_17962625","title":"VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation.","date":"2007","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17962625","citation_count":93,"is_preprint":false},{"pmid":"8627168","id":"PMC_8627168","title":"Human vascular adhesion protein 1 (VAP-1) is a unique sialoglycoprotein that mediates carbohydrate-dependent binding of lymphocytes to endothelial cells.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8627168","citation_count":90,"is_preprint":false},{"pmid":"17548577","id":"PMC_17548577","title":"The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17548577","citation_count":88,"is_preprint":false},{"pmid":"9254657","id":"PMC_9254657","title":"Vascular adhesion protein 1 (VAP-1) mediates lymphocyte subtype-specific, selectin-independent recognition of vascular endothelium in human lymph nodes.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9254657","citation_count":85,"is_preprint":false},{"pmid":"27036009","id":"PMC_27036009","title":"Myofibroblasts are distinguished from activated skin fibroblasts by the expression of AOC3 and other associated markers.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27036009","citation_count":83,"is_preprint":false},{"pmid":"11156953","id":"PMC_11156953","title":"Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo.","date":"2001","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/11156953","citation_count":72,"is_preprint":false},{"pmid":"23407548","id":"PMC_23407548","title":"VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23407548","citation_count":71,"is_preprint":false},{"pmid":"8625974","id":"PMC_8625974","title":"Lymphocyte binding to vascular endothelium in inflamed skin revisited: a central role for vascular adhesion protein-1 (VAP-1).","date":"1996","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8625974","citation_count":59,"is_preprint":false},{"pmid":"20538694","id":"PMC_20538694","title":"Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.","date":"2010","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/20538694","citation_count":58,"is_preprint":false},{"pmid":"25889951","id":"PMC_25889951","title":"Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration.","date":"2015","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/25889951","citation_count":50,"is_preprint":false},{"pmid":"23943052","id":"PMC_23943052","title":"PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo.","date":"2013","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23943052","citation_count":44,"is_preprint":false},{"pmid":"21435467","id":"PMC_21435467","title":"VAP-1-mediated M2 macrophage infiltration underlies IL-1β- but not VEGF-A-induced lymph- and angiogenesis.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21435467","citation_count":43,"is_preprint":false},{"pmid":"10864915","id":"PMC_10864915","title":"Human vascular adhesion protein-1 (VAP-1) plays a critical role in lymphocyte-endothelial cell adhesion cascade under shear.","date":"2000","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/10864915","citation_count":38,"is_preprint":false},{"pmid":"15791459","id":"PMC_15791459","title":"Properties of recombinant human N1-acetylpolyamine oxidase (hPAO): potential role in determining drug sensitivity.","date":"2005","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15791459","citation_count":37,"is_preprint":false},{"pmid":"15259025","id":"PMC_15259025","title":"A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte-endothelium interactions under shear stress.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15259025","citation_count":37,"is_preprint":false},{"pmid":"16806498","id":"PMC_16806498","title":"Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis.","date":"2006","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/16806498","citation_count":35,"is_preprint":false},{"pmid":"7589075","id":"PMC_7589075","title":"Different forms of human vascular adhesion protein-1 (VAP-1) in blood vessels in vivo and in cultured endothelial cells: implications for lymphocyte-endothelial cell adhesion models.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7589075","citation_count":35,"is_preprint":false},{"pmid":"22238597","id":"PMC_22238597","title":"Implication for functions of the ectopic adipocyte copper amine oxidase (AOC3) from purified enzyme and cell-based kinetic studies.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22238597","citation_count":34,"is_preprint":false},{"pmid":"22133888","id":"PMC_22133888","title":"VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke.","date":"2011","source":"Cerebrovascular diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/22133888","citation_count":33,"is_preprint":false},{"pmid":"25662771","id":"PMC_25662771","title":"VAP-1 blockade prevents subarachnoid hemorrhage-associated cerebrovascular dilating dysfunction via repression of a neutrophil recruitment-related mechanism.","date":"2015","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25662771","citation_count":32,"is_preprint":false},{"pmid":"17207171","id":"PMC_17207171","title":"Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients.","date":"2007","source":"Journal of the European Academy of Dermatology and Venereology : JEADV","url":"https://pubmed.ncbi.nlm.nih.gov/17207171","citation_count":30,"is_preprint":false},{"pmid":"19204971","id":"PMC_19204971","title":"Circulating form of human vascular adhesion protein-1 (VAP-1): decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis.","date":"2009","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19204971","citation_count":30,"is_preprint":false},{"pmid":"18991279","id":"PMC_18991279","title":"Ischemia-reperfusion injury is attenuated in VAP-1-deficient mice and by VAP-1 inhibitors.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18991279","citation_count":29,"is_preprint":false},{"pmid":"22595173","id":"PMC_22595173","title":"The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1).","date":"2012","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/22595173","citation_count":29,"is_preprint":false},{"pmid":"24304424","id":"PMC_24304424","title":"Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): old target-new inhibition mode.","date":"2013","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24304424","citation_count":28,"is_preprint":false},{"pmid":"17490641","id":"PMC_17490641","title":"VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins.","date":"2007","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17490641","citation_count":28,"is_preprint":false},{"pmid":"22214508","id":"PMC_22214508","title":"Mini-PEG spacering of VAP-1-targeting 68Ga-DOTAVAP-P1 peptide improves PET imaging of inflammation.","date":"2011","source":"EJNMMI research","url":"https://pubmed.ncbi.nlm.nih.gov/22214508","citation_count":28,"is_preprint":false},{"pmid":"23885334","id":"PMC_23885334","title":"The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function.","date":"2013","source":"American journal of clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23885334","citation_count":26,"is_preprint":false},{"pmid":"23664164","id":"PMC_23664164","title":"Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.","date":"2013","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23664164","citation_count":26,"is_preprint":false},{"pmid":"31047972","id":"PMC_31047972","title":"Blood-brain barrier dysfunction underlying Alzheimer's disease is induced by an SSAO/VAP-1-dependent cerebrovascular activation with enhanced Aβ deposition.","date":"2019","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/31047972","citation_count":26,"is_preprint":false},{"pmid":"21585208","id":"PMC_21585208","title":"Identification of two imidazole binding sites and key residues for substrate specificity in human primary amine oxidase AOC3.","date":"2011","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21585208","citation_count":25,"is_preprint":false},{"pmid":"18348872","id":"PMC_18348872","title":"p53 phosphorylation is involved in vascular cell death induced by the catalytic activity of membrane-bound SSAO/VAP-1.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18348872","citation_count":25,"is_preprint":false},{"pmid":"33805974","id":"PMC_33805974","title":"SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33805974","citation_count":24,"is_preprint":false},{"pmid":"19761765","id":"PMC_19761765","title":"Localization of vascular adhesion protein-1 (VAP-1) in the human eye.","date":"2009","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/19761765","citation_count":24,"is_preprint":false},{"pmid":"16556889","id":"PMC_16556889","title":"Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16556889","citation_count":24,"is_preprint":false},{"pmid":"34322017","id":"PMC_34322017","title":"Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34322017","citation_count":23,"is_preprint":false},{"pmid":"17947691","id":"PMC_17947691","title":"VAP-1-deficient mice display defects in mucosal immunity and antimicrobial responses: implications for antiadhesive applications.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17947691","citation_count":23,"is_preprint":false},{"pmid":"11592062","id":"PMC_11592062","title":"Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11592062","citation_count":23,"is_preprint":false},{"pmid":"17034126","id":"PMC_17034126","title":"New efficient substrates for semicarbazide-sensitive amine oxidase/VAP-1 enzyme: analysis by SARs and computational docking.","date":"2006","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17034126","citation_count":23,"is_preprint":false},{"pmid":"21515268","id":"PMC_21515268","title":"Homing-associated molecules CD73 and VAP-1 as targets to prevent harmful inflammations and cancer spread.","date":"2011","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/21515268","citation_count":21,"is_preprint":false},{"pmid":"26912327","id":"PMC_26912327","title":"Evaluation of serum and tissue levels of VAP-1 in colorectal cancer.","date":"2016","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26912327","citation_count":21,"is_preprint":false},{"pmid":"20298739","id":"PMC_20298739","title":"A structure-activity study to identify novel and efficient substrates of the human semicarbazide-sensitive amine oxidase/VAP-1 enzyme.","date":"2010","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/20298739","citation_count":21,"is_preprint":false},{"pmid":"21819380","id":"PMC_21819380","title":"Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases.","date":"2011","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/21819380","citation_count":20,"is_preprint":false},{"pmid":"36200383","id":"PMC_36200383","title":"Vascular adhesion protein-1 (VAP-1) in vascular inflammatory diseases.","date":"2022","source":"VASA. Zeitschrift fur Gefasskrankheiten","url":"https://pubmed.ncbi.nlm.nih.gov/36200383","citation_count":19,"is_preprint":false},{"pmid":"32712883","id":"PMC_32712883","title":"Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity.","date":"2020","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32712883","citation_count":19,"is_preprint":false},{"pmid":"23154672","id":"PMC_23154672","title":"VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients.","date":"2012","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/23154672","citation_count":19,"is_preprint":false},{"pmid":"25457560","id":"PMC_25457560","title":"Cross-talk between Aβ and endothelial SSAO/VAP-1 accelerates vascular damage and Aβ aggregation related to CAA-AD.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/25457560","citation_count":19,"is_preprint":false},{"pmid":"24503888","id":"PMC_24503888","title":"Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia.","date":"2014","source":"Cerebrovascular diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/24503888","citation_count":18,"is_preprint":false},{"pmid":"25116373","id":"PMC_25116373","title":"Endothelial amine oxidase AOC3 transiently contributes to adaptive immune responses in the airways.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25116373","citation_count":16,"is_preprint":false},{"pmid":"23686782","id":"PMC_23686782","title":"Therapeutic advantage of anti-VAP-1 over anti-α4 integrin antibody in concanavalin a-induced hepatitis.","date":"2013","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23686782","citation_count":16,"is_preprint":false},{"pmid":"33845913","id":"PMC_33845913","title":"Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy.","date":"2021","source":"International journal of retina and vitreous","url":"https://pubmed.ncbi.nlm.nih.gov/33845913","citation_count":15,"is_preprint":false},{"pmid":"29175057","id":"PMC_29175057","title":"Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29175057","citation_count":15,"is_preprint":false},{"pmid":"16180338","id":"PMC_16180338","title":"The release of soluble VAP-1/SSAO by 3T3-L1 adipocytes is stimulated by isoproterenol and low concentrations of TNFalpha.","date":"2005","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16180338","citation_count":15,"is_preprint":false},{"pmid":"20849600","id":"PMC_20849600","title":"Human vascular adhesion proteın-1 (VAP-1): serum levels for hepatocellular carcinoma in non-alcoholic and alcoholic fatty liver disease.","date":"2010","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20849600","citation_count":15,"is_preprint":false},{"pmid":"17406965","id":"PMC_17406965","title":"Semicarbazide-sensitive amine oxidase substrates fail to induce insulin-like effects in fat cells from AOC3 knockout mice.","date":"2007","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/17406965","citation_count":15,"is_preprint":false},{"pmid":"31146362","id":"PMC_31146362","title":"Vascular Adhesion Protein-1 (VAP-1) as Predictor of Radiographic Severity in Symptomatic Knee Osteoarthritis in the New York University Cohort.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31146362","citation_count":14,"is_preprint":false},{"pmid":"25279492","id":"PMC_25279492","title":"Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40.","date":"2014","source":"Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia","url":"https://pubmed.ncbi.nlm.nih.gov/25279492","citation_count":14,"is_preprint":false},{"pmid":"23337801","id":"PMC_23337801","title":"Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema.","date":"2012","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23337801","citation_count":14,"is_preprint":false},{"pmid":"26362823","id":"PMC_26362823","title":"Protective effect of the multitarget compound DPH-4 on human SSAO/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose deprivation conditions: an in vitro experimental model of cerebral ischaemia.","date":"2015","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26362823","citation_count":14,"is_preprint":false},{"pmid":"35174543","id":"PMC_35174543","title":"Downregulation of VAP-1 in OSCC suppresses tumor growth and metastasis via NF-κB/IL-8 signaling and reduces neutrophil infiltration.","date":"2022","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35174543","citation_count":13,"is_preprint":false},{"pmid":"31638437","id":"PMC_31638437","title":"Assessment of relationship between serum vascular adhesion protein-1 (VAP-1) and gestational diabetes mellitus.","date":"2019","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/31638437","citation_count":13,"is_preprint":false},{"pmid":"19266512","id":"PMC_19266512","title":"Structure-activity relationships of SSAO/VAP-1 arylalkylamine-based substrates.","date":"2009","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/19266512","citation_count":13,"is_preprint":false},{"pmid":"21737458","id":"PMC_21737458","title":"Reaction of vascular adhesion protein-1 (VAP-1) with primary amines: mechanistic insights from isotope effects and quantitative structure-activity relationships.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21737458","citation_count":13,"is_preprint":false},{"pmid":"23540955","id":"PMC_23540955","title":"Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: part 2.","date":"2013","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23540955","citation_count":13,"is_preprint":false},{"pmid":"33727640","id":"PMC_33727640","title":"NG2/CSPG4, CD146/MCAM and VAP1/AOC3 are regulated by myocardin-related transcription factors in smooth muscle cells.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33727640","citation_count":12,"is_preprint":false},{"pmid":"22547093","id":"PMC_22547093","title":"Benzylamine antihyperglycemic effect is abolished by AOC3 gene invalidation in mice but not rescued by semicarbazide-sensitive amine oxidase expression under the control of aP2 promoter.","date":"2012","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22547093","citation_count":12,"is_preprint":false},{"pmid":"30658395","id":"PMC_30658395","title":"Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30658395","citation_count":12,"is_preprint":false},{"pmid":"17393062","id":"PMC_17393062","title":"Characterization of A7r5 cell line transfected in a stable form by hSSAO/VAP-1 gene (A7r5 hSSAO/VAP-1 cell line).","date":"2007","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/17393062","citation_count":11,"is_preprint":false},{"pmid":"15922392","id":"PMC_15922392","title":"Severe cell fragmentation in the endothelial cell apoptosis induced by snake apoptosis toxin VAP1 is an apoptotic characteristic controlled by caspases.","date":"2005","source":"Toxicon : official journal of the International Society on Toxinology","url":"https://pubmed.ncbi.nlm.nih.gov/15922392","citation_count":10,"is_preprint":false},{"pmid":"18926840","id":"PMC_18926840","title":"Expression of mRNAs coding for VAP1/crotastatin-like metalloproteases in the venom glands of three South American pit vipers assessed by quantitative real-time PCR.","date":"2008","source":"Toxicon : official journal of the International Society on Toxinology","url":"https://pubmed.ncbi.nlm.nih.gov/18926840","citation_count":9,"is_preprint":false},{"pmid":"17393063","id":"PMC_17393063","title":"L-lysine as a recognition molecule for the VAP-1 function of SSAO.","date":"2007","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/17393063","citation_count":9,"is_preprint":false},{"pmid":"15736124","id":"PMC_15736124","title":"VAP1, with cystatin C motif, an oocyte protein encoded by a novel ovarian-specific gene during oogenesis in the common brushtail possum (Trichosurus vulpecula).","date":"2005","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/15736124","citation_count":8,"is_preprint":false},{"pmid":"27997774","id":"PMC_27997774","title":"Assessment of the Relationship Between Serum Vascular Adhesion Protein-1 (VAP-1) and Severity of Calcific Aortic Valve Stenosis.","date":"2015","source":"The Journal of heart valve disease","url":"https://pubmed.ncbi.nlm.nih.gov/27997774","citation_count":7,"is_preprint":false},{"pmid":"39296147","id":"PMC_39296147","title":"AOC3 accelerates lung metastasis of osteosarcoma by recruiting tumor-associated neutrophils, neutrophil extracellular trap formation and tumor vascularization.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39296147","citation_count":6,"is_preprint":false},{"pmid":"32959205","id":"PMC_32959205","title":"Circulating vascular adhesion protein-1(VAP-1): a possible biomarker for liver fibrosis associated with chronic hepatitis B and C.","date":"2020","source":"Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]","url":"https://pubmed.ncbi.nlm.nih.gov/32959205","citation_count":6,"is_preprint":false},{"pmid":"37774061","id":"PMC_37774061","title":"Identification of AOC3 and LRRC17 as Colonic Fibroblast Activation Markers and Their Potential Roles in Colorectal Cancer Progression.","date":"2023","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/37774061","citation_count":5,"is_preprint":false},{"pmid":"31094153","id":"PMC_31094153","title":"Effector gene vap1 based DGGE fingerprinting to assess variation within and among Heterodera schachtii populations.","date":"2018","source":"Journal of nematology","url":"https://pubmed.ncbi.nlm.nih.gov/31094153","citation_count":5,"is_preprint":false},{"pmid":"20012150","id":"PMC_20012150","title":"Histamine oxidation in mouse adipose tissue is controlled by the AOC3 gene-encoded amine oxidase.","date":"2010","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/20012150","citation_count":5,"is_preprint":false},{"pmid":"36176983","id":"PMC_36176983","title":"Increased atherosclerotic plaque in AOC3 knock-out in ApoE-/- mice and characterization of AOC3 in atherosclerotic human coronary arteries.","date":"2022","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36176983","citation_count":4,"is_preprint":false},{"pmid":"38855169","id":"PMC_38855169","title":"Association Between Vascular Adhesion Protein-1 (VAP-1) and MACE in Patients with Coronary Heart Disease: A Cohort Study.","date":"2024","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/38855169","citation_count":4,"is_preprint":false},{"pmid":"23397320","id":"PMC_23397320","title":"Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model.","date":"2013","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/23397320","citation_count":4,"is_preprint":false},{"pmid":"25572340","id":"PMC_25572340","title":"Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition.","date":"2015","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25572340","citation_count":4,"is_preprint":false},{"pmid":"40458597","id":"PMC_40458597","title":"The role of VAP-1 in cardiovascular disease: a review.","date":"2025","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40458597","citation_count":3,"is_preprint":false},{"pmid":"40396328","id":"PMC_40396328","title":"Therapeutic Potential of Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO) Inhibitors: Current Medicinal Chemistry and Emerging Opportunities.","date":"2025","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/40396328","citation_count":3,"is_preprint":false},{"pmid":"35507758","id":"PMC_35507758","title":"ω-(5-Phenyl-2H-tetrazol-2-yl)alkyl-substituted hydrazides and related compounds as inhibitors of amine oxidase copper containing 3 (AOC3).","date":"2022","source":"Archiv der Pharmazie","url":"https://pubmed.ncbi.nlm.nih.gov/35507758","citation_count":3,"is_preprint":false},{"pmid":"38142562","id":"PMC_38142562","title":"ω-(5-Phenyl-2H-tetrazol-2-yl)alkyl-substituted glycine amides and related compounds as inhibitors of the amine oxidase vascular adhesion protein-1 (VAP-1).","date":"2023","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38142562","citation_count":3,"is_preprint":false},{"pmid":"1478972","id":"PMC_1478972","title":"A novel vesicle-associated protein (VAP-1) in sea urchin eggs containing multiple RNA-binding consensus sequences.","date":"1992","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/1478972","citation_count":3,"is_preprint":false},{"pmid":"38741586","id":"PMC_38741586","title":"The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38741586","citation_count":2,"is_preprint":false},{"pmid":"39187313","id":"PMC_39187313","title":"Amine Oxidase, Copper Containing 3 (Aoc3) Knockout Mice Are More Prone to DSS-induced Colitis and Colonic Tumorigenesis.","date":"2024","source":"In vivo (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/39187313","citation_count":1,"is_preprint":false},{"pmid":"24379274","id":"PMC_24379274","title":"VAP-1 in peritoneally dialyzed patients.","date":"2013","source":"Postepy higieny i medycyny doswiadczalnej (Online)","url":"https://pubmed.ncbi.nlm.nih.gov/24379274","citation_count":1,"is_preprint":false},{"pmid":"17083159","id":"PMC_17083159","title":"[Vascular adhesion protein-1 (VAP-1) in inflammatory process].","date":"2006","source":"Przeglad lekarski","url":"https://pubmed.ncbi.nlm.nih.gov/17083159","citation_count":1,"is_preprint":false},{"pmid":"40716438","id":"PMC_40716438","title":"Association of <italic>AOC3</italic> Expression in Visceral Adipose Tissue and Circulating Soluble Vascular Adhesion Protein-1 with Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Japanese Patients with Severe Obesity.","date":"2025","source":"Obesity facts","url":"https://pubmed.ncbi.nlm.nih.gov/40716438","citation_count":0,"is_preprint":false},{"pmid":"41420234","id":"PMC_41420234","title":"Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [68Ga]Ga-DOTA-Siglec-9.","date":"2025","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/41420234","citation_count":0,"is_preprint":false},{"pmid":"41021158","id":"PMC_41021158","title":"Pan-cancer analysis reveals AOC3 as a potential therapeutic biomarker for colorectal cancer.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41021158","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52169,"output_tokens":8344,"usd":0.140834,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18266,"output_tokens":7427,"usd":0.138503,"stage2_stop_reason":"end_turn"},"total_usd":0.279337,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"VAP-1 (AOC3) mediates lymphocyte binding to endothelial cells in a sialic acid-dependent manner; desialylation abolishes lymphocyte binding. The mature 170-kDa surface form is a heavily sialylated glycoprotein, and sialic acids are indispensable for VAP-1 adhesive function.\",\n      \"method\": \"Glycosidase digestion of VAP-1, frozen-section adhesion assay under shear stress, anti-VAP-1 monoclonal antibody blockade\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal glycosidase treatment plus functional adhesion assay, replicated across multiple studies in the corpus\",\n      \"pmids\": [\"8627168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"VAP-1 mediates subtype-specific adhesion of CD8+ T cells and NK cells to peripheral lymph node HEVs under shear in an oligosaccharide-dependent, L-selectin-independent manner. Intravital microscopy confirmed VAP-1 involvement in initial lymphocyte–endothelial contact in vivo.\",\n      \"method\": \"Frozen-section adhesion assay under shear, anti-VAP-1/anti-L-selectin/anti-α4 integrin mAb blockade, intravital microscopy in rabbit mesenteric venules\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal blocking experiments plus in vivo intravital microscopy, replicated in subsequent studies\",\n      \"pmids\": [\"9254657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"A soluble form of VAP-1 (sVAP-1) circulates in human blood; it is slightly larger (by ~10 kDa) than membrane-bound VAP-1 under non-reducing conditions but migrates similarly after reduction. Circulating sVAP-1 retains the ability to modulate lymphocyte binding to endothelial cells.\",\n      \"method\": \"Sandwich ELISA with anti-VAP-1 mAbs, immunoblotting under reducing and non-reducing conditions, in vitro lymphocyte adhesion assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ELISA + immunoblot + functional adhesion assay, single lab\",\n      \"pmids\": [\"9686623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Recombinant VAP-1 cDNA transfected into a non-adherent endothelial cell line reconstitutes shear-dependent lymphocyte binding with preference for CD8+ T cells. CD44 ligation on lymphocytes upregulates VAP-1-dependent adhesion, suggesting CD44 activates the VAP-1 counter-receptor. The RGD motif and enzymatic activity are not required for adhesion.\",\n      \"method\": \"VAP-1 cDNA transfection into endothelial cell line, flow chamber and rotatory adhesion assays under shear, antibody blockade of lymphocyte surface molecules, enzymatic activity mutagenesis/inhibition\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reconstitution by transfection, functional mutagenesis showing RGD and enzyme activity dispensable for adhesion, multiple orthogonal blocking experiments, single lab\",\n      \"pmids\": [\"10864915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"VAP-1 functions as a molecular brake during granulocyte rolling in vivo: anti-VAP-1 mAb treatment in rabbits increased rolling velocity, increased rolling skipping frequency, and reduced firm leukocyte adhesion by ~44%, attenuating ~70% of granulocyte extravasation into an inflammation site.\",\n      \"method\": \"Intravital microscopy in rabbit inflammation model, anti-VAP-1 mAb blockade\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo intravital microscopy with mAb blockade, quantitative rolling/adhesion measurements, single lab\",\n      \"pmids\": [\"11156953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The amine oxidase (enzymatic) activity of VAP-1 is required for PMN transmigration through endothelium: an enzymatically inactive point mutant of VAP-1 abolished transmigration capacity, and specific amine oxidase inhibitors reduced PMN rolling and transmigration under shear stress in vitro and PMN extravasation in vivo.\",\n      \"method\": \"Enzymatically inactive VAP-1 point mutant, amine oxidase inhibitors, flow-dependent in vitro transmigration assay, in vivo animal inflammation model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — point mutant plus pharmacological inhibition plus in vivo model, multiple orthogonal approaches, replicated in subsequent studies\",\n      \"pmids\": [\"14726375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Adipocytes (3T3-L1 cells and human adipose tissue explants) are a source of soluble VAP-1/SSAO generated by metalloprotease-dependent shedding of the membrane form. TNF-α stimulates and insulin modulates this release; metalloprotease inhibitor batimastat blocks it.\",\n      \"method\": \"Detection of sVAP-1 in adipocyte conditioned medium by immunoprecipitation and SSAO activity assay, batimastat (metalloprotease inhibitor) blockade, partial adipose tissue ablation in rats\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell systems (murine 3T3-L1, human explants, in vivo ablation), pharmacological blockade identifying metalloprotease mechanism, single lab\",\n      \"pmids\": [\"14968297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"AOC3/VAP-1-deficient mice show defective leukocyte slow rolling, firm adhesion, and transmigration at inflammatory sites and lymphoid tissues, with reduced lymphocyte homing to lymphoid organs and attenuated peritonitis response, establishing AOC3 as essential for leukocyte extravasation in vivo.\",\n      \"method\": \"AOC3 knockout mice, real-time intravital imaging, peritonitis model, lymphocyte homing assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple in vivo readouts and real-time imaging, replicated across multiple inflammation models\",\n      \"pmids\": [\"15664163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Fetal VAP-1 is expressed from embryonic week 7 in smooth muscle, is dimerized and enzymatically active before birth, and can mediate rolling and firm adhesion of cord blood lymphocytes on HUVEC under shear stress, indicating the protein is functionally intact during human ontogeny.\",\n      \"method\": \"Immunohistochemistry of fetal tissues, adenoviral VAP-1 transfection of HUVEC, flow chamber adhesion assay with cord blood lymphocytes, enzymatic activity measurement\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — adenoviral transfection plus flow chamber functional assay, single lab\",\n      \"pmids\": [\"16556889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The oxidase activity of VAP-1 induces transcription and translation of endothelial E- and P-selectins, thereby promoting leukocyte binding. In VAP-1-deficient mice reconstituted with human VAP-1 transgene, enzyme-dependent P-selectin upregulation was confirmed in HEVs and flat-walled vessels in vivo.\",\n      \"method\": \"Wild-type and enzymatically inactive VAP-1 point mutant transfected endothelial cells, VAP-1 KO mice, humanized VAP-1 transgenic mice, selectin transcription/translation assays, lymphocyte binding assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — enzymatic point mutant plus KO rescue transgenic mice, in vitro and in vivo validation, multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"17548577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"AOC3/VAP-1-deficient mice have reduced IgA concentrations, age-dependent paucity of Peyer's patch lymphocytes, and impaired oral OVA immunization and antimicrobial responses (S. aureus, coxsackie B4), establishing a role for VAP-1 in mucosal immunity.\",\n      \"method\": \"VAP-1 KO mice, oral immunization with OVA, bacterial/viral challenge, flow cytometry, immunoglobulin measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with multiple immune readouts, single lab\",\n      \"pmids\": [\"17947691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SSAO/VAP-1 oxidizes primary amines in adipocytes; substrates including benzylamine and methylamine stimulate glucose transport via an oxidation-dependent (not receptor-mediated) mechanism. AOC3 knockout adipocytes completely lacked the SSAO-dependent glucose uptake response to benzylamine, methylamine, and tyramine.\",\n      \"method\": \"AOC3 knockout mice, hexose transport assay in isolated adipocytes, SSAO activity measurement\",\n      \"journal\": \"Journal of neural transmission\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — definitive genetic KO abolishing both enzymatic and functional response, replicated in subsequent benzylamine studies\",\n      \"pmids\": [\"17406965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SSAO/VAP-1 transmembrane form mediates vascular cell death via methylamine oxidation; the catalytic products activate p53 phosphorylation, induce PUMA-α expression, affect mitochondrial Bcl-2 family proteins, and activate effector caspases, causing cytotoxicity in smooth muscle cells.\",\n      \"method\": \"Stably transfected SSAO-expressing smooth muscle cell line (A7r5), methylamine treatment, cytotoxicity assay, western blot for p53, PUMA-α, Bcl-2 family, caspase activity assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stably transfected cell line with substrate treatment, multiple molecular pathway readouts, single lab\",\n      \"pmids\": [\"18348872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"VAP-1 deficiency in mice attenuates intestinal ischemia-reperfusion injury and acute lung injury. Both enzymatic inhibitors and a function-blocking mAb in wild-type mice replicate the protective phenotype, establishing the catalytic activity of VAP-1 as responsible for its pro-inflammatory action in I/R injury.\",\n      \"method\": \"VAP-1 KO mice, humanized transgenic VAP-1 mice, small molecule enzyme inhibitors, function-blocking mAb, intestinal I/R model with lung injury readout\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO + pharmacological inhibitors + mAb blockade + transgenic rescue, multiple orthogonal approaches\",\n      \"pmids\": [\"18991279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structures of soluble AOC3 from human plasma revealed two imidazole-binding sites: one at the TPQ cofactor (in both off-copper and on-copper conformations) and one in the substrate channel near Tyr394 and Thr212. Single-mutant functional studies identified Met211 and Leu469 as key residues for substrate specificity.\",\n      \"method\": \"X-ray crystallography of soluble human AOC3 (2.6 Å and 2.95 Å resolution), site-directed mutagenesis of Met211, Tyr394, Thr212, Leu469, enzyme activity assays with four substrates, computational docking\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures plus mutagenesis plus enzyme activity assays, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"21585208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Human AOC3 expressed in insect cells oxidizes a broad range of primary amines including dopamine and cysteamine; kinetic profiling shows K(m)(O2) approximates interstitial oxygen partial pressure. Differentiated murine 3T3-L1 adipocytes display uniform cell-surface AOC3 with whole-cell K(m) values close to those of purified enzyme, linking kinetic parameters to adipocyte function.\",\n      \"method\": \"Purified recombinant human and murine AOC3 from insect cells, substrate kinetic profiling, K(m)(O2) measurement, whole-cell kinetics with differentiated 3T3-L1 adipocytes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic characterization of purified recombinant protein plus cell-based validation, single lab, multiple substrates and conditions\",\n      \"pmids\": [\"22238597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"VAP-1 kinetics studied using isotope effects (KIE of 6–7.6 on k(cat)/K(m) with d2-benzylamine; large KIE on k(cat) ~8 with phenylethylamine) established that C-H bond breaking at the TPQ cofactor is the rate-limiting step for substrate oxidation.\",\n      \"method\": \"Soluble VAP-1 expressed in HEK293 EBNA1 cells, steady-state kinetics, primary kinetic isotope effects with deuterated substrates, pH-rate profiles, QSAR analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous mechanistic enzymology with isotope effects and pH profiles, single lab\",\n      \"pmids\": [\"21737458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"VAP-1 expressed in endothelial cells localizes specifically to lipid rafts of the plasma membrane as a dimer, retains enzymatic activity comparable to in vivo, and mediates leukocyte adhesion to endothelium; this adhesion function is not observed in smooth muscle cell lines expressing 3-fold higher VAP-1, indicating cell-type-specific functional context.\",\n      \"method\": \"Stable transfection of human SSAO/VAP-1 into endothelial cell line, lipid raft fractionation, western blot, leukocyte adhesion assay, SSAO enzyme activity assay\",\n      \"journal\": \"Biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable transfection + lipid raft fractionation + functional adhesion assay, single lab\",\n      \"pmids\": [\"21819380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"VAP-1 inhibition blocks IL-1β-induced but not VEGF-A-induced lymphangiogenesis and angiogenesis in the mouse cornea, and this effect is mediated by blockade of M2 macrophage infiltration. VAP-1 was expressed in blood vessels but not in lymphatic vessels in vivo.\",\n      \"method\": \"Corneal micropocket assay with IL-1β or VEGF-A, VAP-1 inhibitor treatment, in vivo molecular imaging of VAP-1 expression, macrophage phenotyping\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo model with molecular imaging and pharmacological inhibition, single lab\",\n      \"pmids\": [\"21435467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Mice carrying an oxidase-activity-null VAP-1 knock-in show the same inflammatory phenotype as VAP-1 null mice in sterile peritonitis and antibody-induced arthritis models, definitively establishing that the oxidase activity is responsible for VAP-1's pro-inflammatory function in vivo.\",\n      \"method\": \"VAP-1 oxidase-null knock-in mice, sterile peritonitis model, antibody-induced arthritis model, comparison to VAP-1 null mice\",\n      \"journal\": \"American journal of clinical and experimental immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in point mutant compared to full knockout in two independent disease models, replicates enzymatic activity requirement established in earlier inhibitor studies\",\n      \"pmids\": [\"23885334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"VAP-1 mediates myeloid cell recruitment during pulmonary metastasis; blocking VAP-1 with a small molecule inhibitor reduces myeloid cell accumulation, tumor cell survival, and metastasis. Simultaneous blockade of VCAM-1 and VAP-1 does not produce additive effects, suggesting closely related mechanisms.\",\n      \"method\": \"VAP-1 small molecule inhibitor, VCAM-1 blocking antibody, murine pulmonary metastasis model, myeloid cell quantification, tumor survival assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological blockade with functional metastasis readout, single lab\",\n      \"pmids\": [\"23407548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"VAP-1 and α4 integrin mediate opposing immune cell recruitment in concanavalin A hepatitis: anti-VAP-1 antibody (blocking adhesion but not amine oxidase activity) reduces IL-4-producing CD4 T cell infiltration and liver injury, while VAP-1-deficient mice show complete abrogation of both activities, confirming VAP-1-dependent CD4 T cell homing to the liver.\",\n      \"method\": \"Anti-VAP-1 mAb, anti-α4 integrin mAb, VAP-1 KO mice, Con A hepatitis model, intravital microscopy, T cell phenotyping\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mAb blockade plus genetic KO, multiple cell population readouts, distinguishes adhesion from enzymatic activity contributions\",\n      \"pmids\": [\"23686782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structures of novel pyridazinone inhibitors in complex with human VAP-1 defined a unique reversible binding site in the active site channel distinct from covalent substrate-based binding; homology modeling identified species-specific amino acid differences explaining the lack of rodent VAP-1 inhibition.\",\n      \"method\": \"X-ray crystallography of inhibitor–hVAP-1 complexes (3 structures), homology modeling, inhibitory activity assays against human and rodent VAP-1\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple crystal structures plus enzyme activity assays, single lab\",\n      \"pmids\": [\"24304424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SSAO/VAP-1 in endothelial cells exacerbates oxygen-glucose deprivation (OGD) damage; methylamine oxidation during OGD increases cell death via caspase-3 and caspase-8 activation. OGD also triggers metalloproteinase-2-dependent shedding of soluble SSAO/VAP-1 and induces SSAO-dependent leukocyte adhesion partly through its enzymatic activity.\",\n      \"method\": \"Stably transfected hSSAO/VAP-1 endothelial cell line, OGD model, metalloproteinase inhibitors, western blot for caspases, leukocyte adhesion assay, SSAO enzymatic substrate treatment\",\n      \"journal\": \"Cerebrovascular diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable transfection plus pharmacological inhibition plus multiple functional readouts, single lab\",\n      \"pmids\": [\"24503888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SSAO/VAP-1 enhances Aβ1-40 (Dutch mutant) and Aβ1-42 deposition on vascular cells by mechanisms both dependent and independent of its enzymatic activity. Conversely, Dutch-mutated Aβ1-40 increases SSAO-dependent cell toxicity and increases SSAO protein availability at endothelial membranes, establishing a bidirectional cross-talk between SSAO and Aβ in CAA pathology.\",\n      \"method\": \"Vascular cell models stably expressing SSAO, Aβ peptide treatment, SSAO enzymatic activity inhibition, Aβ deposition quantification, cell toxicity assay\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable expression system with enzymatic inhibition distinguishing activity-dependent and -independent mechanisms, single lab\",\n      \"pmids\": [\"25457560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SSAO/VAP-1 expression in endothelial cells alters the pro-inflammatory and pro-angiogenic angioneurin release (particularly IL-6, IL-8, VEGF), decreases tight-junction proteins (zona occludens, claudin-5), increases BBB permeability and leukocyte adhesion, and enhances vascular Aβ deposition by mechanisms both dependent and independent of enzymatic activity, linking SSAO to BBB dysfunction in Alzheimer's disease.\",\n      \"method\": \"In vitro BBB models (hCMEC/D3 cells expressing or not expressing hSSAO/VAP-1), cytokine ELISA, western blot for tight-junction proteins, permeability assay, leukocyte adhesion assay, Aβ deposition assay\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isogenic cell lines differing only in SSAO expression, multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"31047972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The obesity phenotype of AOC3 knockout mice (increased adiposity, loss of benzylamine insulin-like action in adipocytes, downregulated adipose inflammatory markers) is fully reproduced in AOC3 knock-in mice expressing oxidase-activity-null VAP-1, establishing that the SSAO enzymatic activity is required for the metabolic functions of VAP-1 in adipose tissue.\",\n      \"method\": \"AOC3 KO mice vs. AOC3 oxidase-activity knock-in mice, body composition, adipocyte glucose transport assay, lipid profile, adipose tissue inflammation markers, SSAO activity measurement\",\n      \"journal\": \"Journal of physiology and biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — parallel KO and enzymatic knock-in comparison across multiple metabolic readouts, two independent genetic models\",\n      \"pmids\": [\"32712883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AOC3/VAP-1 is a transcriptional target of myocardin-related transcription factors (MRTFs: MYOCD, MRTF-A/MKL1, MRTF-B/MKL2) acting through serum response factor (SRF) in smooth muscle cells. MRTF overexpression increases AOC3 mRNA and protein; SRF silencing reduces AOC3 transcript levels; AOC3 promoter reporter activity is increased by MRTF-A and depends on chromatin remodeling enzyme KDM3A.\",\n      \"method\": \"Bioinformatics correlation, MRTF overexpression in human SMCs, SRF siRNA knockdown, promoter-reporter assay, qPCR, western blot, immunofluorescence imaging\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter plus overexpression plus knockdown with multiple readouts, single lab\",\n      \"pmids\": [\"33727640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In mouse adipose tissue, histamine is oxidized predominantly by SSAO (AOC3 product): AOC3 knockout abolished histamine oxidation in adipose tissue but not in intestine, where diamine oxidase (AOC1) predominates. Loss of adipose SSAO-mediated histamine oxidation unmasked a lipolytic effect of histamine in adipocytes.\",\n      \"method\": \"AOC3 KO mice, tissue amine oxidase activity assay (hydrogen peroxide production), lipolysis assay (glycerol release) in isolated adipocytes, real-time PCR for AOC1/AOC2/MAOA/MAOB\",\n      \"journal\": \"Inflammation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with multiple tissue and functional readouts, discriminates AOC3 from related enzymes\",\n      \"pmids\": [\"20012150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"AOC3 is a marker of myofibroblasts (identified as the target of mAb PR2D3) and is expressed on the cell surface in a trypsin- and collagenase-sensitive manner. TGFβ substantially downregulates AOC3 expression in myofibroblasts but dramatically increases αSMA in skin fibroblasts, distinguishing these two cell types.\",\n      \"method\": \"Identification of AOC3 as mAb PR2D3 target protein, surface trypsin/collagenase digestion assay, FACS sorting, TGFβ treatment, whole-genome microarray, NKX2-3 knockdown, qPCR/western blot\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mAb target identification plus multiple functional cell biology assays, single lab\",\n      \"pmids\": [\"27036009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"AOC3 knockout in ApoE-/- mice paradoxically increased atherosclerotic plaque size at early stages, associated with VSMC dedifferentiation, decreased contractile markers, increased MCP-1, and higher CD3+ T cell recruitment. AOC3 was confirmed to be expressed mainly by VSMCs and slightly by endothelium, but not by macrophages in plaques.\",\n      \"method\": \"ApoE-/-/AOC3-/- double knockout mice, immunohistochemistry, western blot, confocal microscopy, qPCR, human VSMC treatment with AOC3 inhibitor LJP1586\",\n      \"journal\": \"Frontiers in cardiovascular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO in atherosclerosis model with multiple cell markers and in vitro validation, single lab\",\n      \"pmids\": [\"36176983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"AOC3 promotes lung metastasis of osteosarcoma by recruiting tumor-associated neutrophils; activated neutrophil extracellular traps (NETs) upregulate metastatic capacity of OS cells, and AOC3 also supports tumor neovascularization. Downregulation of AOC3 inhibits OS cell migration, invasion, and angiogenesis in vitro and reduces lung metastasis in vivo, mediated through NF-κB/IL-8 signaling.\",\n      \"method\": \"siRNA knockdown of AOC3 in OS cells, transwell/wound healing assay, tube formation assay, sphere-forming assay, C57BL/6 xenograft lung metastasis model, flow cytometry for neutrophil recruitment, immunofluorescence for NETs, ELISA\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro knockdown plus in vivo xenograft model, multiple functional readouts, single lab\",\n      \"pmids\": [\"39296147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Simvastatin blocks soluble SSAO/VAP-1 release into the bloodstream after ischemic stimulus and prevents E-selectin and VCAM-1 overexpression, in part through interaction with SSAO/VAP-1-dependent pathways, while not acting as a direct enzymatic inhibitor of SSAO in vitro.\",\n      \"method\": \"In vitro ischemia model in hSSAO/VAP-1-expressing endothelial cells, in vivo stroke model, SSAO activity assay, western blot for E-selectin and VCAM-1, leukocyte adhesion assay\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isogenic cell lines expressing or not expressing SSAO, in vivo stroke model, but simvastatin mechanism indirect, single lab\",\n      \"pmids\": [\"29175057\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AOC3/VAP-1 is a homodimeric, cell-surface copper-containing amine oxidase expressed on endothelial cells, smooth muscle cells, and adipocytes that possesses both adhesive and enzymatic functions: its TPQ cofactor oxidizes primary amines to produce hydrogen peroxide, ammonia, and aldehydes, and this catalytic activity is required (as shown by enzymatically inactive point mutants and knockout mice) for leukocyte slow rolling, firm adhesion, and transmigration at inflammatory sites, in part by inducing endothelial P- and E-selectin expression; the soluble form is shed by metalloprotease-dependent cleavage; in adipocytes the enzyme mediates SSAO-substrate-stimulated glucose uptake; and the protein's transcription in smooth muscle cells is driven by the MRTF-SRF pathway via KDM3A-dependent chromatin remodeling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AOC3/VAP-1 is a homodimeric, sialylated cell-surface copper-containing amine oxidase that couples a dual adhesive and enzymatic role in directing leukocyte traffic across endothelium during inflammation [#0, #7]. It mediates shear-resistant, oligosaccharide-dependent binding of CD8+ T cells and NK cells to high endothelial venules independently of L-selectin, and acts as a molecular brake on leukocyte rolling that promotes firm adhesion and transmigration in vivo [#1, #3, #4]. Genetic ablation establishes AOC3 as essential for leukocyte slow rolling, firm adhesion, extravasation, lymphocyte homing, and mucosal immunity [#7, #10]. The enzymatic and adhesive functions are mechanistically linked: the TPQ-cofactor-dependent oxidation of primary amines is required for transmigration and drives transcriptional induction of endothelial E- and P-selectins, and oxidase-activity-null knock-in mice phenocopy the full knockout in sterile peritonitis and arthritis, definitively assigning the pro-inflammatory action to catalysis [#5, #9, #19]. Mechanistic enzymology and crystallography of the soluble form define a TPQ cofactor with rate-limiting C–H bond cleavage, copper-coordinating active-site geometry, and substrate-specificity residues (Met211, Leu469) within the substrate channel [#14, #16]. In adipose tissue the same oxidase activity mediates amine-substrate-stimulated glucose uptake and an insulin-like metabolic action, with knock-in studies showing enzymatic activity is required for the metabolic phenotype [#11, #26]. A soluble form is generated by metalloprotease-dependent shedding from adipocytes and endothelium and circulates in blood [#2, #6]. AOC3 transcription in smooth muscle cells is driven by myocardin-related transcription factors acting through SRF and KDM3A-dependent chromatin remodeling [#27].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that VAP-1's adhesive activity toward lymphocytes depends on its heavy sialylation, defining it as a glycosylation-dependent endothelial adhesion molecule before its enzymatic identity was known.\",\n      \"evidence\": \"Glycosidase digestion plus frozen-section adhesion under shear and mAb blockade\",\n      \"pmids\": [\"8627168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the lymphocyte counter-receptor not defined\", \"Relationship between adhesion and any catalytic function not yet addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated subtype-specific, L-selectin-independent adhesion of CD8+ T and NK cells to HEVs and confirmed VAP-1 involvement in initial lymphocyte–endothelial contact in vivo.\",\n      \"evidence\": \"Frozen-section shear adhesion with orthogonal mAb blockade and rabbit intravital microscopy\",\n      \"pmids\": [\"9254657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Counter-receptor still unidentified\", \"Mechanistic basis of cell-type preference unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified a circulating soluble form of VAP-1 retaining adhesion-modulating activity, raising the possibility of a regulated shed pool.\",\n      \"evidence\": \"Sandwich ELISA, reducing/non-reducing immunoblot, and in vitro adhesion assay\",\n      \"pmids\": [\"9686623\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism and protease responsible for shedding not defined\", \"Physiological role of soluble form unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Reconstitution by transfection proved VAP-1 is sufficient to confer shear-dependent CD8+ adhesion and showed RGD motif and enzymatic activity are dispensable for adhesion itself, separating adhesion from catalysis.\",\n      \"evidence\": \"VAP-1 cDNA transfection, flow chamber adhesion, lymphocyte mAb blockade, activity mutagenesis\",\n      \"pmids\": [\"10864915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CD44-VAP-1 counter-receptor link inferred but not molecularly mapped\", \"Did not reconcile enzyme-independent adhesion with later enzyme-dependent transmigration\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined VAP-1 functionally as a molecular brake on granulocyte rolling that converts rolling to firm adhesion and enables extravasation in vivo.\",\n      \"evidence\": \"Rabbit intravital microscopy with quantitative rolling/adhesion measurements and mAb blockade\",\n      \"pmids\": [\"11156953\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether enzymatic activity underlies the braking effect\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed that the amine oxidase activity is required for PMN transmigration, linking catalysis to leukocyte trafficking for the first time.\",\n      \"evidence\": \"Enzymatically inactive point mutant, amine oxidase inhibitors, flow transmigration assay, in vivo model\",\n      \"pmids\": [\"14726375\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of the oxidase products not identified at this stage\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified adipocytes as a source of soluble VAP-1 generated by metalloprotease-dependent shedding regulated by TNF-α and insulin, defining how the soluble pool arises.\",\n      \"evidence\": \"Adipocyte conditioned-medium immunoprecipitation/SSAO assay with batimastat blockade and in vivo adipose ablation\",\n      \"pmids\": [\"14968297\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific metalloprotease not identified\", \"Functional consequence of shed enzyme not resolved here\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic knockout established AOC3 as essential for leukocyte slow rolling, firm adhesion, transmigration, and lymphocyte homing in vivo.\",\n      \"evidence\": \"AOC3 knockout mice with real-time intravital imaging, peritonitis, and homing assays\",\n      \"pmids\": [\"15664163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not isolate enzymatic from adhesive contribution genetically\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected oxidase activity to a transcriptional output by showing enzyme-dependent induction of endothelial E- and P-selectins, providing a molecular bridge between catalysis and adhesion.\",\n      \"evidence\": \"WT vs enzyme-null point-mutant endothelial cells, KO and humanized transgenic mice, selectin transcription/translation assays\",\n      \"pmids\": [\"17548577\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway from H2O2/aldehyde products to selectin transcription not fully mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extended AOC3 function to mucosal immunity, showing KO mice have reduced IgA, Peyer's patch defects, and impaired oral/antimicrobial responses.\",\n      \"evidence\": \"AOC3 KO mice with oral immunization, pathogen challenge, and immunoglobulin measurement\",\n      \"pmids\": [\"17947691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular mechanism linking VAP-1 to IgA and Peyer's patch development unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated that adipocyte AOC3 oxidase activity mediates amine-substrate-stimulated glucose transport via an oxidation-dependent, non-receptor mechanism.\",\n      \"evidence\": \"AOC3 KO adipocyte hexose transport assays with multiple amine substrates and SSAO activity measurement\",\n      \"pmids\": [\"17406965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between oxidation products and glucose transporter mobilization not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed catalytic products of methylamine oxidation can drive vascular smooth muscle cytotoxicity via p53/PUMA/caspase signaling, implicating the enzyme in cell death.\",\n      \"evidence\": \"Stably transfected SSAO smooth muscle cells with methylamine treatment and apoptotic pathway western blots/caspase assays\",\n      \"pmids\": [\"18348872\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression system; physiological substrate concentrations not validated\", \"In vivo relevance not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified histamine as a tissue-selective AOC3 substrate in adipose tissue and revealed that its oxidation restrains a lipolytic effect, distinguishing AOC3 from AOC1.\",\n      \"evidence\": \"AOC3 KO mice, tissue amine oxidase and lipolysis assays, expression profiling of related enzymes\",\n      \"pmids\": [\"20012150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological regulation of histamine oxidation in human adipose not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Solved crystal structures of soluble human AOC3 and defined active-site/substrate-channel residues governing substrate specificity, providing a structural framework for catalysis and inhibitor design.\",\n      \"evidence\": \"X-ray crystallography at 2.6/2.95 Å with site-directed mutagenesis and substrate activity assays\",\n      \"pmids\": [\"21585208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the membrane-bound full-length dimer not determined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established C–H bond cleavage at the TPQ cofactor as the rate-limiting catalytic step through kinetic isotope effects.\",\n      \"evidence\": \"Steady-state kinetics with deuterated substrates, pH-rate profiles, QSAR on soluble VAP-1\",\n      \"pmids\": [\"21737458\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address regulation of catalysis in the cellular membrane context\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Profiled the broad primary-amine substrate range and showed KmO2 approximates interstitial oxygen, linking enzyme kinetics to adipocyte physiology.\",\n      \"evidence\": \"Purified recombinant human/murine AOC3 kinetics and whole-cell 3T3-L1 adipocyte measurements\",\n      \"pmids\": [\"22238597\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the dominant physiological substrate in vivo not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Localized active VAP-1 dimers to endothelial lipid rafts and showed adhesion function is cell-type-context dependent, absent in smooth muscle cells despite higher expression.\",\n      \"evidence\": \"Stable transfection, lipid raft fractionation, adhesion and enzyme assays\",\n      \"pmids\": [\"21819380\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of cell-type-specific adhesion competence unexplained\", \"Single overexpression system\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Oxidase-activity-null knock-in mice phenocopied full knockout in peritonitis and arthritis, definitively assigning the pro-inflammatory function to catalytic activity.\",\n      \"evidence\": \"Oxidase-null knock-in mice compared to null mice in two inflammation models\",\n      \"pmids\": [\"23885334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address whether residual adhesion contributes in other disease contexts\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Implicated VAP-1 in pulmonary metastasis through myeloid cell recruitment, with mechanistic overlap with VCAM-1.\",\n      \"evidence\": \"Small-molecule VAP-1 inhibitor and VCAM-1 mAb in a murine metastasis model with myeloid quantification\",\n      \"pmids\": [\"23407548\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether enzymatic vs adhesive activity drives this not separated\", \"Single lab pharmacological approach\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Distinguished VAP-1's adhesion versus enzymatic contributions in liver inflammation, showing adhesion-blocking mAb reduces CD4 T cell homing while KO abrogates both.\",\n      \"evidence\": \"Anti-VAP-1 and anti-α4 mAbs, KO mice, Con A hepatitis, intravital microscopy, T cell phenotyping\",\n      \"pmids\": [\"23686782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative quantitative contribution of adhesion vs catalysis not fully partitioned\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined a reversible pyridazinone inhibitor binding site in the active-site channel and rationalized species-specific inhibition, advancing structure-based drug design.\",\n      \"evidence\": \"Three inhibitor–hVAP-1 crystal structures, homology modeling, human/rodent activity assays\",\n      \"pmids\": [\"24304424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of these inhibitors not addressed in this study\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked SSAO/VAP-1 methylamine oxidation to ischemic endothelial death and showed OGD triggers MMP-2-dependent shedding, connecting the enzyme to cerebrovascular injury.\",\n      \"evidence\": \"Stably transfected endothelial cells under OGD with MMP inhibitors, caspase blots, adhesion assays\",\n      \"pmids\": [\"24503888\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression system; endogenous relevance untested\", \"MMP-2 as shedding protease shown only pharmacologically\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established bidirectional cross-talk between SSAO/VAP-1 and amyloid-β in cerebral amyloid angiopathy, with both enzyme-dependent and -independent components.\",\n      \"evidence\": \"Vascular cells stably expressing SSAO, Aβ treatment, enzymatic inhibition, deposition and toxicity assays\",\n      \"pmids\": [\"25457560\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzyme-independent mechanism of Aβ enhancement not defined\", \"Overexpression model only\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified AOC3 as a surface marker of myofibroblasts that is downregulated by TGFβ, distinguishing it from αSMA-defined fibroblast states.\",\n      \"evidence\": \"mAb PR2D3 target identification, surface protease digestion, FACS, TGFβ treatment, microarray\",\n      \"pmids\": [\"27036009\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of AOC3 in myofibroblast biology not established\", \"Mechanism of TGFβ regulation unmapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed simvastatin suppresses ischemia-induced soluble SSAO release and selectin/VCAM-1 expression via SSAO-dependent pathways without direct enzyme inhibition.\",\n      \"evidence\": \"Isogenic SSAO-expressing endothelial cells, in vivo stroke model, activity and adhesion assays\",\n      \"pmids\": [\"29175057\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Indirect mechanism; statin target intersecting SSAO pathway not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked endothelial SSAO/VAP-1 to blood-brain-barrier dysfunction through altered cytokine release, tight-junction loss, increased permeability, and Aβ deposition in Alzheimer's models.\",\n      \"evidence\": \"Isogenic hCMEC/D3 BBB models with cytokine ELISA, tight-junction blots, permeability and adhesion assays\",\n      \"pmids\": [\"31047972\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo BBB validation lacking\", \"Enzyme-independent component mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated through parallel KO and oxidase-null knock-in mice that SSAO enzymatic activity is required for VAP-1's adipose metabolic functions, mirroring the inflammatory enzyme-dependence.\",\n      \"evidence\": \"AOC3 KO vs oxidase-null knock-in mice, body composition, adipocyte glucose transport, inflammation markers\",\n      \"pmids\": [\"32712883\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effector linking oxidation to insulin-like glucose uptake not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the transcriptional control of AOC3 in smooth muscle cells, identifying it as an MRTF/SRF target dependent on KDM3A-mediated chromatin remodeling.\",\n      \"evidence\": \"MRTF overexpression, SRF siRNA, promoter-reporter assays, qPCR/western blot in human SMCs\",\n      \"pmids\": [\"33727640\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream signals activating MRTF/SRF on the AOC3 locus not defined\", \"In vivo confirmation lacking\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a paradoxical protective role for AOC3 in early atherosclerosis, where KO increased plaque size and VSMC dedifferentiation, confirming VSMC-dominant expression in plaques.\",\n      \"evidence\": \"ApoE-/-/AOC3-/- mice, immunohistochemistry, contractile marker blots, human VSMC inhibitor treatment\",\n      \"pmids\": [\"36176983\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which AOC3 loss promotes VSMC dedifferentiation unresolved\", \"Stage-dependence not fully characterized\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed AOC3 promotes osteosarcoma lung metastasis by recruiting tumor-associated neutrophils and driving NET formation and angiogenesis via NF-κB/IL-8 signaling.\",\n      \"evidence\": \"AOC3 siRNA knockdown, migration/invasion/tube/sphere assays, xenograft metastasis model, NET imaging\",\n      \"pmids\": [\"39296147\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymatic vs adhesive contribution not separated\", \"Direct AOC3-NF-κB/IL-8 link not mechanistically defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identity of the lymphocyte/leukocyte counter-receptor and the precise signaling chain connecting amine-oxidation products (H2O2, aldehyde, ammonia) to selectin induction and glucose transport remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Counter-receptor for VAP-1-mediated adhesion not molecularly identified\", \"Signal transduction from oxidase products to transcriptional and metabolic outputs incompletely mapped\", \"Structure of full-length membrane dimer unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [5, 9, 11, 14, 15, 16, 28]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 1, 3, 4, 7]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [11, 15, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 5, 9, 17]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 5, 7, 9, 10, 19, 21]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [11, 26, 28]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 1, 3, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}